Protagonist Therapeutics, Inc. Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc.

PTGX

Kedudukan dalam Saham #2251
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Harga Saham
$138.50
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$8.96B
Perubahan (1 hari)
3.02%
Perubahan (1 tahun)
84.67%
Negara
US
Perdagangan Protagonist Therapeutics, Inc. (PTGX)

Kategori

Healthcare
Sejarah pecahan saham untuk Protagonist Therapeutics, Inc. (PTGX)
Saham Protagonist Therapeutics, Inc. (simbol: PTGX) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 21, 2026.
Satu saham PTGX yang dibeli sebelum Oct 21, 2026 kini bersamaan dengan 0 saham PTGX.
Senarai pecahan saham
Tahun Pecahan Gandaan Gandaan Kumulatif
Tidak cukup data untuk tarikh yang disediakan.
Pecahan saham untuk syarikat pesaing atau serupa
Syarikat Bilangan pecahan saham Gandaan Kumulatif Negara
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL